Finding The Exit: Forbion On Roche’s Acquisition Of Inflazome
Executive Summary
Two years after leading a $46m series B financing round in Inflazome, a four-year old Irish biotech developing oral NLRP3 inflammasome inhibitors, VC firm Forbion is celebrating Roche’s $446m acquisition of the company, which includes the potential for additional milestone payments. Forbion general partner Marco Boorsa, who joined Inflazome’s board of directors in November 2018, spoke with In Vivo about the VC firm’s investment strategy.
You may also be interested in...
Roche Bulks Up In NLRP3 With €380m Inflazome Buy
Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.
Bayer Hopeful Of Sweet Success With KaNDy Buy
Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.
Exit Interview: Ken Kaitin On 35 Years At Tufts Center For Study Of Drug Development
At the end of December 2020, Kenneth Kaitin retired as director of the Tufts Center for the Study of Drug Development after 23 years in the role, and 35 years working with the CSDD. Kenneth Getz, previously professor and deputy director of the CSDD, succeeds Kaitin as director in 2021.
Need a specific report? 1000+ reports available
Buy Reports